Researchers found that taking Femara, Novartis AG's breast cancer pill, up to seven years after finishing tamoxifen therapy lowered the risk of breast cancer recurrence in post-menopausal patients by 63%. The drug, an aromatase inhibitor, slashed metastasis risk by 61% and lowered the risk of tumor growth in the unaffected breast by more than 80% percent, according to the study.

Full Story:

Related Summaries